Ischemic heart disease after renal transplantation

Kidney International

Volumn 61, Issue 1, 2002, Pages 356-369

  Kasiske, Bertram L ^a   Cohen, Jordan J ^a   Harrington, John T ^a   Madias, Nicolaos E ^a   Rabb, Hamid ^a   Rosenberg, Mark ^a   Herzog, Charles A ^a   Aaronson, Michael ^a   Adrogué, Horacio Esteban ^a   Anjum, Shakeel ^a   Berkseth, Robert ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

HDL cholesterol; LDL cholesterol; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; AZATHIOPRINE; CHOLESTEROL; CORTICOSTEROID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; VITAMIN; WARFARIN;

ADULT; CARDIOVASCULAR RISK; CASE REPORT; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CHRONIC GLOMERULONEPHRITIS; CIGARETTE SMOKING; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DISEASE COURSE; GLUCOSE INTOLERANCE; GRAFT REJECTION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; MALE; POSTOPERATIVE CARE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW;

EID: 0036149250     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00121.x     Document Type: Article

References (73)

1. Clinical epidemiology of cardiovascular disease in chronic renal disease
2. Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure
3. Cardiovascular disease after renal transplantation
4. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography
5. The evaluation of renal transplant candidates: Clinical practice guidelines
6. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
7. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
8. Blood pressure lowering treatment trialists' Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials
9. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
10. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomized controlled trials
11. For the American Society of Transplantation: Recommendations for the outpatient surveillance of renal transplant recipients
12. Association of chronic kidney graft failure with recipient blood pressure
13. Arterial hypertension and renal allograft survival
14. Racial differences in renal allograft survival: The role of systemic hypertension
15. Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients
16. Explained and unexplained ischemic heart disease risk after renal transplantation
17. Prediction of coronary heart disease using risk factor categories
18. Hypertension in patients with chronic renal disease
19. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
20. Summary of the Third Report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III)
21. Hyperlipidemia in patients with chronic renal disease
22. Low-density lipoprotein metabolism following renal transplantation
23. Fat clearances and hyperlipidaemia in renal allograft recipients - The role of insulin resistance
24. Increased low density lipoprotein oxidation in stable kidney transplant recipients
25. Hyperlipidaemia in renal transplant patients
26. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation
27. Lipid and lipoprotein(a) in renal transplant recipients
28. Hyperlipidemia in long-term survivors of pediatric renal transplantation
29. Lipid relationships in dialysis and renal transplant patients
30. Abnormal serum lipid patterns in primary renal allograft recipients
31. Hyperlipidaemia in renal transplant patients
32. Serum lipoprotein(a) levels in chronic renal failure and renal transplant patients
33. Serum lipoprotein(a) levels in patients with chronic renal failure - Evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: A prospective study
34. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?
35. Risk factors for accelerated atherosclerosis in renal transplant recipients
36. Role of lipid disturbances in the atherosclerosis of renal transplant patients
37. Cardiovascular risk factors and diseases after renal transplantation
38. Cardiovascular morbidity and risk factors in renal transplant patients
39. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: A Southeastern Organ Procurement Foundation multicenter clinical study
40. Cigarette smoking in renal transplant recipients
41. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant
42. Patient survival after renal transplantation; more than 25 years follow-up
43. Chronic rejection in renal allografts: Importance of cardiovascular risk factors
44. Smoking cessation: Principles and practice based upon the AHCPR Guideline, 1996, Agency for Health Care Policy and Research
45. The agency for health care policy and research smoking cessation clinical practice guideline
46. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial
47. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
48. Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients
49. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients
50. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors
51. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease
52. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
53. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence
54. Hyperhomocysteinaemia: A significant risk factor for cardiovascular disease in renal transplant recipients
55. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study
56. Treatment with high-dose folic acid effectively lowers plasma homocysteine concentration in cyclosporine-treated renal transplant recipients
57. Treatment of hyperhomocysteinemia in renal transplant recipients
58. Antioxidants and atherosclerotic heart disease
59. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
60. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association
61. Aspirin therapy in diabetes
62. North of England evidence based guideline development project: Guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care
63. A metaregression analysis of the dose-response effect of aspirin on stroke
64. Aspirin prophylaxis for the primary prevention of myocardial infarction
65. Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporin-treated renal allograft recipients
66. Oxygen free radicals and platelet and granulocyte aggregability in renal transplant patients
67. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study
68. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
69. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant
70. Association of chronic kidney graft failure with recipient blood pressure
71. Long-term cardiovascular morbidity and mortality in autosomal dominant polycystic kidney disease patients after renal transplantation
72. Cardiovascular risk factors in renal transplant patients: Cyclosporine A versus tacrolimus